Skip to main content
Evidence Snapshot

NCI-H1975

CHEMBL614348 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:59Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614348
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NCI-H1975 as ChEMBL target CHEMBL614348. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NCI-H1975
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614348
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why NCI-H1975 matters

As of 2026-09-13

NCI-H1975 is reviewed as NCI-H1975; the current evidence base includes 41 approved drugs, 3951 compounds, and 1738 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 41 approved drugs, 3951 compounds, and 1738 assays for this target. The dominant activity type is IC50. CHEMBL3353410 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3353410 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
41 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why NCI-H1975 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3951
Total Compounds
1738
Total Assays
41
Approved Drugs
IC50: 3539.0, EC50: 98.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3353410
11.0 IC50 Approved
No preferred name
CHEMBL5590430
10.9 IC50
No preferred name
CHEMBL4793880
10.7 IC50
No preferred name
CHEMBL5592293
10.6 IC50
No preferred name
CHEMBL5584148
10.6 IC50

Approved Drugs

Structure Compound First Approval
2018
NERATINIB
CHEMBL180022
2017
ABEMACICLIB
CHEMBL3301610
2017
BRIGATINIB
CHEMBL3545311
2017
OLMUTINIB
CHEMBL3786343
2016
PANOBINOSTAT
CHEMBL483254
2015
OSIMERTINIB
CHEMBL3353410
2015
AFATINIB
CHEMBL1173655
2013
IBRUTINIB
CHEMBL1873475
2013
2009
DASATINIB
CHEMBL5416410
2006
VINORELBINE
CHEMBL553025
1994
PACLITAXEL
CHEMBL428647
1992
ETOPOSIDE
CHEMBL44657
1983
DAUNORUBICIN
CHEMBL178
1979
DOXORUBICIN
CHEMBL53463
1974
1974
VINBLASTINE
CHEMBL159
1965
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:59Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614348